Safety Profile of Cilta-Cel: Saad Z. Usmani, MD, MBA, FACP
The director of Clinical Research in Hematologic Malignancies at Levine Cancer Institute discussed adverse events in the CARTITUDE-1 trial.
This content originally appeared on our sister site, CancerNetwork®.
CancerNetwork® spoke with Saad Z. Usmani, MD, MBA, FACP, of the Levine Cancer Institute in Charlotte, North Carolina, to discuss the safety profile of the phase 1b/2 CARTITUDE-1 trial that looked at patients with relapsed/refractory multiple myeloma treated with ciltacabtagene autoleucel (cilta-cel). These findings were presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
Transcription:
For CARTITUDE-1, there were no new safety updates because the more common adverse events that we observe with CAR T-cell therapies—not just with the previously reported [B-cell maturation antigen]–directed CAR T-cells, but also with CD19 CAR T-cells—[are] hematologic AEs. Those were quite common and consistent with what has been reported in the past. The same is true for [cytokine release syndrome (CRS)]. Ninety-two patients out of the 97 had CRS, but most of those were grade 1 or grade 2, and CRS resolved in 99% of the patients within 14 days of onset.
